Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Numbers to judge from

First of all we know the original claim in CA was minimum $ 200 M (including Sony and Fujitsu but without JVC) and second the payment of more than $ 30 M from one of the companies, that settled during the case. Another helpfull indication of importance could be the marketcap of these companies.

 

I believe that the minimum was at least $300 M(several hundreds ie more than 2 or 3). Dividing the target settlement by 5 is also problematic because those that settled received the early mover discount, those remaining in the litigation would therefore be expected to pay more as the discount has gone, and they protracted the case.

Litigation costs would be part of the settlement ie the loser pays.

By removing the license fees paid by previous defendants, add the extra time and loss of discounted licenses, plus the potential for triple damages at trial, I would suggest a potential range between $750 M and $1,100 M. Obviously, these would be reduced because of any pre-trial settlement. On this basis, I would confirm my prior estimate of PTSC's net share being not less than $175 M(pay $350 M now, or face the potential liability of $1,100 M at trial).

The "domino effect" should see at least 30 additional licences(those most advanced in negotiations) during this quarter, giving a net asset value, per share, in excess of $1.00.

 

Now the math gets interesting.

 

 

 

Be well

Share
New Message
Please login to post a reply